PARP1 and ovarian carcinoma: Olaparib can be used in ovarian cancer patients who are having only partial response to chemotherapeutic agents as it enhances the cytotoxicity of DNA-damaging agents and can reverse tumor cell chemoresistance by inhibiting PARP [277].